Insider Buying: Enovis (NYSE:ENOV) Insider Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were bought at an average price of $24.77 per share, for a total transaction of $24,770.00. Following the completion of the purchase, the insider directly owned 44,640 shares in the company, valued at $1,105,732.80. This represents a 2.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, March 4th, Oliver Engert bought 250 shares of Enovis stock. The shares were purchased at an average price of $25.10 per share, for a total transaction of $6,275.00.
• On Friday, February 27th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00.

Enovis Stock Performance

NYSE ENOV traded down $1.50 on Thursday, reaching $24.29. The stock had a trading volume of 1,449,100 shares, compared to its average volume of 1,097,264. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a market cap of $1.39 billion, a P/E ratio of -1.17 and a beta of 1.46. The business’s 50-day moving average price is $24.15 and its 200 day moving average price is $28.08. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The firm had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis Corporation will post 2.79 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. BTIG Research boosted their price target on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Canaccord Genuity Group lowered their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Finally, Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and an average price target of $47.43.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners purchased a new position in Enovis in the 4th quarter valued at about $29,000. Farther Finance Advisors LLC boosted its stake in Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after buying an additional 367 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in Enovis during the second quarter worth approximately $46,000. Finally, SJS Investment Consulting Inc. increased its holdings in shares of Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.